Rosmantuzumab (25 mg/kg; i.p., once a week for 4 weeks) significantly protects the animals from developing liver fibrosis[1].
Rosmantuzumab (25 mg/kg; i.p., once for two weeks, for total 6 weeks) significantly inhibits skin thickness, collagen deposition, and number of α-SMA positive cells in bleomycin-induced lung fibrosis mouse models[1].
| Animal Model: | Male C57B1/6J CCl4 liver fibrosis mouse models[1] |
| Dosage: | 25 mg/kg |
| Administration: | Intraperitoneal injection; 25 mg/kg, once a week for 4 weeks |
| Result: | Significantly decreased collagen I and collagen III mRNAs, and inhibits β-catenin cytoplasmic and nuclear translocation.
|
